GWP GW Pharm.

TIDMGWP

RNS Number : 4818Q

GW Pharmaceuticals PLC

30 November 2016

GW Pharmaceuticals to Report Q4 and Year-End Financial Results and Host Conference Call on 5 December, 2016

London, UK, 30 Nov 2016: GW Pharmaceuticals plc (Nasdaq: GWPH, AIM: GWP, "GW" or "the Company"), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, will announce on 5 December, 2016 its fourth quarter and year-end financial results for the period ending 30 September, 2016. GW will also host a conference call the same day at 8:00 a.m. EST (1:00 p.m. GMT). Conference call information will be provided in the financial results press release. A replay of the call will also be available through the Company's website (www.gwpharm.com) shortly after the call.

About GW Pharmaceuticals plc

Founded in 1998, GW is a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform in a broad range of disease areas. GW is advancing an orphan drug program in the field of childhood epilepsy with a focus on Epidiolex(R) (cannabidiol), which is in Phase 3 clinical development for the treatment of Dravet syndrome, Lennox-Gastaut syndrome, Tuberous Sclerosis Complex and Infantile Spasms. GW commercialized the world's first plant-derived cannabinoid prescription drug, Sativex(R) , which is approved for the treatment of spasticity due to multiple sclerosis in 30 countries outside the United States. The Company has a deep pipeline of additional cannabinoid product candidates which includes compounds in Phase 1 and 2 trials for glioma, schizophrenia and epilepsy. For further information, please visit www.gwpharm.com.

Enquiries:

 
 GW Pharmaceuticals plc 
 Stephen Schultz, VP Investor        917 280 2424 / 401 500 
  Relations (U.S.)                    6570 
 
 FTI Consulting (Media Enquiries) 
 Ben Atwell / Simon Conway           +44 20 3727 1000 
 
   Peel Hunt LLP (UK NOMAD) 
 James Steel                         +44 20 7418 8900 
 
 

This information is provided by RNS

The company news service from the London Stock Exchange

END

NORUKAKRNNAAUAA

(END) Dow Jones Newswires

November 30, 2016 08:00 ET (13:00 GMT)

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From Apr 2024 to May 2024

Gw Pharmaceuticals (LSE:GWP)
Historical Stock Chart
From May 2023 to May 2024